Cancerimmunterapi til behandling af hæmatologisk cancer

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Standard

Cancerimmunterapi til behandling af hæmatologisk cancer. / Holmström, Morten Orebo; Klausen, Uffe; Jørgensen, Nicolai Grønne; Holmberg, Staffan; Grauslund, Jacob; Met, Özcan; Svane, Inge Marie; Pedersen, Lars Møller; Knudsen, Lene Meldgaard; Hasselbalch, Hans Carl; Andersen, Mads Hald.

I: Ugeskrift for Laeger, Bind 181, Nr. 10, V06180421, 2019.

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Harvard

Holmström, MO, Klausen, U, Jørgensen, NG, Holmberg, S, Grauslund, J, Met, Ö, Svane, IM, Pedersen, LM, Knudsen, LM, Hasselbalch, HC & Andersen, MH 2019, 'Cancerimmunterapi til behandling af hæmatologisk cancer', Ugeskrift for Laeger, bind 181, nr. 10, V06180421. <https://ugeskriftet.dk/videnskab/cancerimmunterapi-til-behandling-af-haematologisk-cancer>

APA

Holmström, M. O., Klausen, U., Jørgensen, N. G., Holmberg, S., Grauslund, J., Met, Ö., Svane, I. M., Pedersen, L. M., Knudsen, L. M., Hasselbalch, H. C., & Andersen, M. H. (2019). Cancerimmunterapi til behandling af hæmatologisk cancer. Ugeskrift for Laeger, 181(10), [V06180421]. https://ugeskriftet.dk/videnskab/cancerimmunterapi-til-behandling-af-haematologisk-cancer

Vancouver

Holmström MO, Klausen U, Jørgensen NG, Holmberg S, Grauslund J, Met Ö o.a. Cancerimmunterapi til behandling af hæmatologisk cancer. Ugeskrift for Laeger. 2019;181(10). V06180421.

Author

Holmström, Morten Orebo ; Klausen, Uffe ; Jørgensen, Nicolai Grønne ; Holmberg, Staffan ; Grauslund, Jacob ; Met, Özcan ; Svane, Inge Marie ; Pedersen, Lars Møller ; Knudsen, Lene Meldgaard ; Hasselbalch, Hans Carl ; Andersen, Mads Hald. / Cancerimmunterapi til behandling af hæmatologisk cancer. I: Ugeskrift for Laeger. 2019 ; Bind 181, Nr. 10.

Bibtex

@article{7979210c962b4a2bb72e2083f12dbc7a,
title = "Cancerimmunterapi til behandling af h{\ae}matologisk cancer",
abstract = "Cancer immune therapy is now used routinely for the treatment of several solid malignancies, albeit just recently having entered the clinic for treatment of haematological malignancies. Several studies demonstrate that cancer immune therapy is a promising treatment modality for the latter. Especially treatment with chimeric antigen receptor T cells for acute lymphoblastic leukaemia and lymphoma is promising. Other promising treatment modalities are immune check point inhibitors for both lymphoid and myeloid malignancies, as well as therapeutic cancer vaccination targeting tumour antigens.",
keywords = "Antigens, Neoplasm, Hematologic Neoplasms/therapy, Humans, Immunotherapy, Myeloproliferative Disorders",
author = "Holmstr{\"o}m, {Morten Orebo} and Uffe Klausen and J{\o}rgensen, {Nicolai Gr{\o}nne} and Staffan Holmberg and Jacob Grauslund and {\"O}zcan Met and Svane, {Inge Marie} and Pedersen, {Lars M{\o}ller} and Knudsen, {Lene Meldgaard} and Hasselbalch, {Hans Carl} and Andersen, {Mads Hald}",
year = "2019",
language = "Dansk",
volume = "181",
journal = "Ugeskrift for Laeger",
issn = "0041-5782",
publisher = "Almindelige Danske Laegeforening",
number = "10",

}

RIS

TY - JOUR

T1 - Cancerimmunterapi til behandling af hæmatologisk cancer

AU - Holmström, Morten Orebo

AU - Klausen, Uffe

AU - Jørgensen, Nicolai Grønne

AU - Holmberg, Staffan

AU - Grauslund, Jacob

AU - Met, Özcan

AU - Svane, Inge Marie

AU - Pedersen, Lars Møller

AU - Knudsen, Lene Meldgaard

AU - Hasselbalch, Hans Carl

AU - Andersen, Mads Hald

PY - 2019

Y1 - 2019

N2 - Cancer immune therapy is now used routinely for the treatment of several solid malignancies, albeit just recently having entered the clinic for treatment of haematological malignancies. Several studies demonstrate that cancer immune therapy is a promising treatment modality for the latter. Especially treatment with chimeric antigen receptor T cells for acute lymphoblastic leukaemia and lymphoma is promising. Other promising treatment modalities are immune check point inhibitors for both lymphoid and myeloid malignancies, as well as therapeutic cancer vaccination targeting tumour antigens.

AB - Cancer immune therapy is now used routinely for the treatment of several solid malignancies, albeit just recently having entered the clinic for treatment of haematological malignancies. Several studies demonstrate that cancer immune therapy is a promising treatment modality for the latter. Especially treatment with chimeric antigen receptor T cells for acute lymphoblastic leukaemia and lymphoma is promising. Other promising treatment modalities are immune check point inhibitors for both lymphoid and myeloid malignancies, as well as therapeutic cancer vaccination targeting tumour antigens.

KW - Antigens, Neoplasm

KW - Hematologic Neoplasms/therapy

KW - Humans

KW - Immunotherapy

KW - Myeloproliferative Disorders

M3 - Tidsskriftartikel

C2 - 30869069

VL - 181

JO - Ugeskrift for Laeger

JF - Ugeskrift for Laeger

SN - 0041-5782

IS - 10

M1 - V06180421

ER -

ID: 238487309